Article Type
Audio
Changed
Fri, 01/04/2019 - 11:12
Display Headline
David Henry's JCSO podcast, January 2016

In his January podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses a Commentary by Dr Thomas Strouse on the use on cannabinoids in the cancer treatment setting and a Community Translations article on the recent approval of idarucizumab as the first specific oral anticoagulant reversal agent. Also included in the line-up are two Review articles, one on new therapies for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting and another on the management of epidermal growth factor receptor inhibitor-associated rash; and Original Reports on cyclical hypofractionated radiotherapy for palliative treatment in locally advanced head and neck cancer and on the impact of surgery for early-stage non-small-cell lung cancer on patient quality of life.

 

Listen to the podcast below.

 

 

Publications
The Journal of Community and Supportive Oncology
MDedge Hematology and Oncology
Legacy Keywords
cannabis, medical marijuana, palliative treatment, tetrahydrocannabinol, THC, cannabidiol, CBD, chemotherapy-induced nausea and vomiting, CINV, loss of appetite, venous thromboembolism, VTE, deep venous thrombosis, pulmonary embolism, idarucizumab, humanized monoclonal antibody fragment, reversal agent, thrombin, direct oral anticoagulants, DOACs, dabigatran, rivaroxaban, apixaban, edoxaban, andexanet alfa, epidermal growth factor receptor inhibitors, EGFRIs, skin toxicities, rash, quality of life, QoL, antibiotics, topical corticosteroids, antihistamines, pre-emptive treatment, reactive treatment, patient-reported outcomes, locally advanced head and neck cancer, cyclical hypofractionated radiotherapy, Quad Shot, delayed late fibrosis, squamous cell carcinoma, intensity-modulated radiation therapy, IMRT, pain, dysphagia, Food Intake Level Scale, lung cancer, stage IA, impact of surgery, I-ELCAP, non-small-cell lung cancer, NSCLC, Short Form Health Survey, SF-12
Sections
David Henry's JCSO Podcast

In his January podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses a Commentary by Dr Thomas Strouse on the use on cannabinoids in the cancer treatment setting and a Community Translations article on the recent approval of idarucizumab as the first specific oral anticoagulant reversal agent. Also included in the line-up are two Review articles, one on new therapies for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting and another on the management of epidermal growth factor receptor inhibitor-associated rash; and Original Reports on cyclical hypofractionated radiotherapy for palliative treatment in locally advanced head and neck cancer and on the impact of surgery for early-stage non-small-cell lung cancer on patient quality of life.

 

Listen to the podcast below.

 

 

In his January podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses a Commentary by Dr Thomas Strouse on the use on cannabinoids in the cancer treatment setting and a Community Translations article on the recent approval of idarucizumab as the first specific oral anticoagulant reversal agent. Also included in the line-up are two Review articles, one on new therapies for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting and another on the management of epidermal growth factor receptor inhibitor-associated rash; and Original Reports on cyclical hypofractionated radiotherapy for palliative treatment in locally advanced head and neck cancer and on the impact of surgery for early-stage non-small-cell lung cancer on patient quality of life.

 

Listen to the podcast below.

 

 

Publications
The Journal of Community and Supportive Oncology
MDedge Hematology and Oncology
Publications
The Journal of Community and Supportive Oncology
MDedge Hematology and Oncology
Article Type
Audio
Display Headline
David Henry's JCSO podcast, January 2016
Display Headline
David Henry's JCSO podcast, January 2016
Legacy Keywords
cannabis, medical marijuana, palliative treatment, tetrahydrocannabinol, THC, cannabidiol, CBD, chemotherapy-induced nausea and vomiting, CINV, loss of appetite, venous thromboembolism, VTE, deep venous thrombosis, pulmonary embolism, idarucizumab, humanized monoclonal antibody fragment, reversal agent, thrombin, direct oral anticoagulants, DOACs, dabigatran, rivaroxaban, apixaban, edoxaban, andexanet alfa, epidermal growth factor receptor inhibitors, EGFRIs, skin toxicities, rash, quality of life, QoL, antibiotics, topical corticosteroids, antihistamines, pre-emptive treatment, reactive treatment, patient-reported outcomes, locally advanced head and neck cancer, cyclical hypofractionated radiotherapy, Quad Shot, delayed late fibrosis, squamous cell carcinoma, intensity-modulated radiation therapy, IMRT, pain, dysphagia, Food Intake Level Scale, lung cancer, stage IA, impact of surgery, I-ELCAP, non-small-cell lung cancer, NSCLC, Short Form Health Survey, SF-12
Legacy Keywords
cannabis, medical marijuana, palliative treatment, tetrahydrocannabinol, THC, cannabidiol, CBD, chemotherapy-induced nausea and vomiting, CINV, loss of appetite, venous thromboembolism, VTE, deep venous thrombosis, pulmonary embolism, idarucizumab, humanized monoclonal antibody fragment, reversal agent, thrombin, direct oral anticoagulants, DOACs, dabigatran, rivaroxaban, apixaban, edoxaban, andexanet alfa, epidermal growth factor receptor inhibitors, EGFRIs, skin toxicities, rash, quality of life, QoL, antibiotics, topical corticosteroids, antihistamines, pre-emptive treatment, reactive treatment, patient-reported outcomes, locally advanced head and neck cancer, cyclical hypofractionated radiotherapy, Quad Shot, delayed late fibrosis, squamous cell carcinoma, intensity-modulated radiation therapy, IMRT, pain, dysphagia, Food Intake Level Scale, lung cancer, stage IA, impact of surgery, I-ELCAP, non-small-cell lung cancer, NSCLC, Short Form Health Survey, SF-12
Sections
David Henry's JCSO Podcast
Disallow All Ads
Alternative CME